Understanding the impact of gold and silver signals on ERAS applications: A survey of hematology/oncology fellowship program directors.

C Courtney Nicole Miller-Chism (Baylor College of Medicine Division of Hematology/Oncology, Houston, TX) J Julia Lee Close (ASCO, Alexandria, VA) L Lyudmila Bazhenova (University of California, San Diego, San Diego, CA, US) J Jed A. Katzel (Kaiser Permanente, San Francsico, San Francisco, CA) R Reema Anil Patel (University of Kentucky, Lexington, KY) K Karine Tawagi (2University of Illinois Chicago, Chicago, United States) M Mark Riffon (ASCO, Alexandria, VA) M Michael Rothe (Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany) A Abbey Prather (ASCO, Alexandria, VA) R Rami Manochakian (Mayo Clinic Florida, Jacksonville, FL)

Abstract

9007 Background: Since transition to virtual interviews, application and interview inflation have increased the work burden of GME recruitment. In 2021, AAMC ERAS implemented a process that allows applicants to assign signals to top programs of interest. There is a paucity of guidance on optimal use of ERAS signals (ES), resulting in apprehension and uncertainty amongst applicants and program directors (PD). For the 2026 ERAS cycle, Hematology/Oncology programs (HOP) had the option to participate in ES, in which applicants are provided 5 gold (G) signals and 15 silver (S) signals. First-hand knowledge on how ES was utilized by HOP, as well as PD perceptions about ES, may guide best practices on ES. Methods: During the ASCO Oncology Training Program Leadership Retreat in November 2025, an anonymous survey, assessing HOP utilization and perception of ES, and the impact of ES on recruitment practices, was launched. One PD from each HOP was invited to complete the survey while onsite. Results: 88 HOP (46% of ACGME HOP) are represented. 97% (n=85) utilized ES. Of HOP who used ES, 74% are academic. 32% are small (1-9 fellows), 43% medium (10-19 fellows), and 25% large (20+ fellows). 79% received 400+ applications. 69% reviewed applications without signals but gave higher consideration to signaled applicants. 25% only reviewed applications with signals. 28% used ES when creating rank list; 45% think ES utilization is appropriate during ranking. 85% reported ES did not alter their approach to applicants requiring visa sponsorship. 78% felt ES made the interview selection process easier. 66% were more satisfied with this year’s recruitment process compared to years without ES. The most requested change to ES was reduction of allowed signals, especially silver. 98% will use ES next year. Conclusions: Despite limited knowledge on ES impact on recruitment, nearly all surveyed HOP participated in ES this past year and will continue. Most HOP view ES positively though many desire changes, particularly with the number of signals. Most HOP consider all applications regardless of ES. However, some HOP with larger applicant pool are using ES as inclusion criteria for interview consideration. Signals are a strong predictor for interview invitation when internal selection criteria are met. The “borderline” applicant may be the greatest benefactor from ES, viewed similarly to the non-signaled applicant who meets internal selection criteria. Sharing PD perspectives and real-life data from this year’s ES process breeds opportunities for further improvement and increased confidence with ES. Likelihood HOP offer interview invitation based on quality of application and signals (%, n=85). Internal Selection Criteria Signal Extremely Likely Likely Neutral Unlikely Extremely Unlikely Met G 73 22 5 0 0 S 42 47 8 2 1 None 8 27 24 22 19 Nearly met G 4 35 39 19 3 S 0 9 52 28 11 Not met G 0 2 12 41 45 S 1 1 6 30 62

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
Pages 9007-9007
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (10)

C

Courtney Nicole Miller-Chism

Baylor College of Medicine Division of Hematology/Oncology, Houston, TX

J

Julia Lee Close

ASCO, Alexandria, VA

L

Lyudmila Bazhenova

University of California, San Diego, San Diego, CA, US

J

Jed A. Katzel

Kaiser Permanente, San Francsico, San Francisco, CA

R

Reema Anil Patel

University of Kentucky, Lexington, KY

K

Karine Tawagi

2University of Illinois Chicago, Chicago, United States

M

Mark Riffon

ASCO, Alexandria, VA

M

Michael Rothe

Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany

A

Abbey Prather

ASCO, Alexandria, VA

R

Rami Manochakian

Mayo Clinic Florida, Jacksonville, FL